Identification of mimotopes by screening of a bacterially displayed random peptide library and its use in eliciting an immune response to native HBV-preS
| Autor: | Ning Sheng Shao, Zhong Tao Xin, Jie Zhang, Ya Ping Gao, Yan Ning Xue, Chuan Liu, Can Quan Mao, An Zhao, Shi Gan Ling |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Hepatitis B virus
medicine.drug_class Blotting Western Enzyme-Linked Immunosorbent Assay Monoclonal antibody medicine.disease_cause Antibodies Viral Epitope Epitopes Mice Antigen Peptide Library medicine Animals Cloning Molecular Protein Precursors Peptide library Mice Inbred BALB C Hepatitis B Surface Antigens General Veterinary General Immunology and Microbiology biology Public Health Environmental and Occupational Health Antibodies Monoclonal DNA Virology Bacterial vaccine Infectious Diseases Monoclonal biology.protein Molecular Medicine Female Antibody |
| Zdroj: | Vaccine. 21(27-30) |
| ISSN: | 0264-410X |
| Popis: | Bacterially-displayed peptide libraries have been widely used as an alternative to phage-displayed peptide libraries in screening epitopes or mimotopes of antibodies. Using a protective monoclonal antibody (mAb) 3B9 against hepatitis B virus (HBV) preS protein as target, mimotopes were successfully screened from a FliTrx™ random peptide library. To monitor the enrichment ratios of each round and to isolate higher affinity clones from the library, a modified procedure was performed in which the titer of eluted bacteria from an antibody-coated well ( P value) was compared with that from a non-coated well ( N value). After sufficient enrichment of the library, bacterial colonies were randomly picked and identified further by the monoclonal bacterial P / N value assay and Western blotting analysis. Immunization of mice with the selected bacterially-displayed mimotopes, including the enriched populations without clone identification, elicited strong specific immune responses against the recombinant preS protein. The present study provides a potentially rapid and effective strategy for the development of engineered live bacterial vaccines without the need for information about the aetiological agents or their antigens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect